Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Darifenacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.98 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 1/20 | 0.98 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | HRH2 | P25021 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darifenacin SCHEMBL3662174 | 1.00 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL2774455 | 0.99 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL56574 | 0.99 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL113331 | 0.99 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL31257801 | 0.99 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL1318587 | 0.98 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL453486 | 0.98 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL1023445 | 0.98 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL5085916 | 0.98 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL1973347 | 0.98 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 514 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066037-A1 | CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-02-29 | — | — | US | disclosed |
| CN-116194114-A | Cathepsin inhibitors for preventing or treating viral infections | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-4125919-A1 | CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-02-08 | — | — | EP | disclosed |
| US-11555040-B2 | Oxepinopyrazole derivatives as inhibitors of P13-kinase activity | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-01-17 | — | — | US | disclosed |
| CN-110785420-B | Oxazepin derivatives as inhibitors of PI 3-kinase activity | 葛兰素史克知识产权开发有限公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3612536-B1 | OXEPINOPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3-KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-12-15 | — | — | EP | disclosed |
| CN-108884046-B | Chemical compounds as inhibitors of kinase activity | 葛兰素史克知识产权开发有限公司 | 2021-11-09 | — | — | CN | disclosed |
| WO-2021191875-A1 | CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-09-30 | — | — | WO | disclosed |
| EP-1962932-B1 | MEDICAMENT DISPENSER | GLAXO GROUP LTD (GB) | 2021-09-08 | — | — | EP | disclosed |
| EP-3260453-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| EP-1644397-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2006-04-12 | — | — | EP | disclosed |
| EP-1644398-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2006-04-12 | — | — | EP | disclosed |
| WO-2006015870-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| US-20060019964-A1 | Antiallergens; antiinflammatory agents; rhinitis; serotonin receptor antagonist | GLAXO GROUP LIMITED (GB) | 2006-01-26 | — | — | US | disclosed |
| WO-2006003407-A2 | CHIMERIC AND HUMANISED MONOCLONAL ANTIBODIES AGAINST INTELEUKIN- 13 | GLAXO GROUP LIMITED (GB) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006000398-A1 | 2,3-BENZOXAZIN DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| WO-2006000401-A1 | SUBSTITUTED OXAZINES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005116037-A1 | PURINE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005005451-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005005452-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066037-A1 | CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS | CTSV, CTSS, CTSA | CHRM3 4791/4885CHRM2 4864/4885CHRM5 4883/4885 |
| US-20060019964-A1 | Antiallergens; antiinflammatory agents; rhinitis; serotonin receptor antagonist | HRH2, HRH4, HRH1 | CHRM3 734/4885CHRM2 1361/4885CHRM5 1285/4885 |
| US-11555040-B2 | Oxepinopyrazole derivatives as inhibitors of P13-kinase activity | CDK3, CDK13, AKT3 | CHRM3 1182/4885CHRM2 1917/4885CHRM5 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.